Sibutramine does not decrease the number of 5-HT re-uptake sites in rat brain and, like fluoxetine, protects against the deficits produced by dexfenfluramine
The effect of sibutramine and dexfenfluramine on 5-HT re-uptake sites, labelled with [ 3H]paroxetine, have been determined in various rat brain regions. In addition, the ability of fluoxetine and sibutramine to protect against the changes in [ 3H]paroxetine binding produced by dexfenfluramine was ex...
Gespeichert in:
Veröffentlicht in: | Neuropharmacology 2000-01, Vol.39 (11), p.2028-2035 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 2035 |
---|---|
container_issue | 11 |
container_start_page | 2028 |
container_title | Neuropharmacology |
container_volume | 39 |
creator | Cheetham, S.C Viggers, J.A Slater, N.A Heal, D.J |
description | The effect of sibutramine and dexfenfluramine on 5-HT re-uptake sites, labelled with [
3H]paroxetine, have been determined in various rat brain regions. In addition, the ability of fluoxetine and sibutramine to protect against the changes in [
3H]paroxetine binding produced by dexfenfluramine was examined. Sibutramine (9 mg/kg, p.o.) and dexfenfluramine (1, 3 and 10 mg/kg, p.o.) were administered twice daily (before 09.00 h and after 16.00 h) for four days, followed by a 14 day drug-free period. In the protection studies, fluoxetine (10 mg/kg, i.p.) and sibutramine (9 mg/kg, p.o.) were given 1 h prior to dexfenfluramine (10 mg/kg, p.o.) using the same dosing regimen as described above. Sibutramine (9 mg/kg, p.o.; three times its ED
50 to inhibit food intake at 2 h) had no significant effect on the number or affinity of 5-HT re-uptake sites the brain regions studied. In contrast, dexfenfluramine at an equivalent dose (3 mg/kg, p.o.) significantly decreased the number of 5-HT re-uptake sites in frontal cortex (by 35%), hippocampus (by 47%) and hypothalamus (by 27%). This effect was dose-dependent with marked decreases (by 58–84%) in the number of sites following 10 mg/kg, p.o. These effects were not associated with changes in binding affinity. Fluoxetine (10 mg/kg, i.p.) completely blocked the effect of dexfenfluramine (10 mg/kg, p.o.) without having any significant effect alone. Sibutramine (9 mg/kg, p.o.) also blocked the effects of dexfenfluramine, although the reversal was only partial in frontal cortex, hippocampus and hypothalamus. Thus sibutramine, unlike dexfenfluramine, does not alter brain 5-HT re-uptake sites. Furthermore, sibutramine and fluoxetine protect against the deficits in 5-HT re-uptake sites produced by dexfenfluramine. These data provide further evidence that sibutramine is a 5-HT re-uptake inhibitor and it does not have neurotoxic potential. |
doi_str_mv | 10.1016/S0028-3908(00)00032-0 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_17632837</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0028390800000320</els_id><sourcerecordid>17632837</sourcerecordid><originalsourceid>FETCH-LOGICAL-c421t-2af05a82e09b2ee77ee9ac90c28c7a659b5866102ec1469e5f25cdc6d8e0d2ba3</originalsourceid><addsrcrecordid>eNqFkcFu1TAQRS1ERV8LnwDyAiGQGhg7ieOsKlQVWqkSi5a15dhjMCTOw3ZQ-zH8a92XJ2DXla2ZMzNX9xLyksF7Bkx8uAbgsqp7kG8B3gFAzSt4QjZMdnXVgWieks1f5JAcpfSjQI1k8hk5ZNCLumvEhvy59sOSo558QGpnTDTMmVo0EXVCmr8jDcs0YKSzo211cUMjVss2659Ik8-F94FGnekQdfnpYE_o6EvTjct8i7msPaHbOGc0OVH9rUAp79ZadN74Uixduxi0dLgrxVuHocyuip6TA6fHhC_27zH5-un85uyiuvry-fLs41VlGs5yxbWDVkuO0A8csesQe216MFyaTou2H1opBAOOhjWix9bx1lgjrESwfND1MXmz7i1afi2Yspp8MjiOOuC8JMU6UXNZdwVsV9DEOaWITm2jn3S8UwzUQy5ql4t6MF0BqF0uCsrcq_2BZZjQ_je1BlGA13tAJ6NHF3UwPv3jGiGElAU7XTEsbvz2GFUyHkNxz8fisLKzf0TJPaO0rFY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17632837</pqid></control><display><type>article</type><title>Sibutramine does not decrease the number of 5-HT re-uptake sites in rat brain and, like fluoxetine, protects against the deficits produced by dexfenfluramine</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Cheetham, S.C ; Viggers, J.A ; Slater, N.A ; Heal, D.J</creator><creatorcontrib>Cheetham, S.C ; Viggers, J.A ; Slater, N.A ; Heal, D.J</creatorcontrib><description>The effect of sibutramine and dexfenfluramine on 5-HT re-uptake sites, labelled with [
3H]paroxetine, have been determined in various rat brain regions. In addition, the ability of fluoxetine and sibutramine to protect against the changes in [
3H]paroxetine binding produced by dexfenfluramine was examined. Sibutramine (9 mg/kg, p.o.) and dexfenfluramine (1, 3 and 10 mg/kg, p.o.) were administered twice daily (before 09.00 h and after 16.00 h) for four days, followed by a 14 day drug-free period. In the protection studies, fluoxetine (10 mg/kg, i.p.) and sibutramine (9 mg/kg, p.o.) were given 1 h prior to dexfenfluramine (10 mg/kg, p.o.) using the same dosing regimen as described above. Sibutramine (9 mg/kg, p.o.; three times its ED
50 to inhibit food intake at 2 h) had no significant effect on the number or affinity of 5-HT re-uptake sites the brain regions studied. In contrast, dexfenfluramine at an equivalent dose (3 mg/kg, p.o.) significantly decreased the number of 5-HT re-uptake sites in frontal cortex (by 35%), hippocampus (by 47%) and hypothalamus (by 27%). This effect was dose-dependent with marked decreases (by 58–84%) in the number of sites following 10 mg/kg, p.o. These effects were not associated with changes in binding affinity. Fluoxetine (10 mg/kg, i.p.) completely blocked the effect of dexfenfluramine (10 mg/kg, p.o.) without having any significant effect alone. Sibutramine (9 mg/kg, p.o.) also blocked the effects of dexfenfluramine, although the reversal was only partial in frontal cortex, hippocampus and hypothalamus. Thus sibutramine, unlike dexfenfluramine, does not alter brain 5-HT re-uptake sites. Furthermore, sibutramine and fluoxetine protect against the deficits in 5-HT re-uptake sites produced by dexfenfluramine. These data provide further evidence that sibutramine is a 5-HT re-uptake inhibitor and it does not have neurotoxic potential.</description><identifier>ISSN: 0028-3908</identifier><identifier>EISSN: 1873-7064</identifier><identifier>DOI: 10.1016/S0028-3908(00)00032-0</identifier><identifier>PMID: 10963746</identifier><identifier>CODEN: NEPHBW</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>5-HT re-uptake sites ; [ 3H]Paroxetine binding ; Animals ; Appetite Depressants - pharmacology ; Biological and medical sciences ; Brain - drug effects ; Brain - metabolism ; Cyclobutanes - pharmacology ; Dexfenfluramine ; Dexfenfluramine - antagonists & inhibitors ; Dexfenfluramine - pharmacology ; Fluoxetine ; Fluoxetine - pharmacology ; Male ; Medical sciences ; Neuropharmacology ; Neurotransmitters. Neurotransmission. Receptors ; Paroxetine - metabolism ; Pharmacology. Drug treatments ; Rat brain ; Rats ; Rats, Sprague-Dawley ; selective serotonin reuptake inhibitors ; Serotonin Receptor Agonists - pharmacology ; Serotonin Uptake Inhibitors - pharmacology ; Serotoninergic system ; Sibutramine</subject><ispartof>Neuropharmacology, 2000-01, Vol.39 (11), p.2028-2035</ispartof><rights>2000 Elsevier Science Ltd</rights><rights>2000 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c421t-2af05a82e09b2ee77ee9ac90c28c7a659b5866102ec1469e5f25cdc6d8e0d2ba3</citedby><cites>FETCH-LOGICAL-c421t-2af05a82e09b2ee77ee9ac90c28c7a659b5866102ec1469e5f25cdc6d8e0d2ba3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0028-3908(00)00032-0$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1466688$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10963746$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cheetham, S.C</creatorcontrib><creatorcontrib>Viggers, J.A</creatorcontrib><creatorcontrib>Slater, N.A</creatorcontrib><creatorcontrib>Heal, D.J</creatorcontrib><title>Sibutramine does not decrease the number of 5-HT re-uptake sites in rat brain and, like fluoxetine, protects against the deficits produced by dexfenfluramine</title><title>Neuropharmacology</title><addtitle>Neuropharmacology</addtitle><description>The effect of sibutramine and dexfenfluramine on 5-HT re-uptake sites, labelled with [
3H]paroxetine, have been determined in various rat brain regions. In addition, the ability of fluoxetine and sibutramine to protect against the changes in [
3H]paroxetine binding produced by dexfenfluramine was examined. Sibutramine (9 mg/kg, p.o.) and dexfenfluramine (1, 3 and 10 mg/kg, p.o.) were administered twice daily (before 09.00 h and after 16.00 h) for four days, followed by a 14 day drug-free period. In the protection studies, fluoxetine (10 mg/kg, i.p.) and sibutramine (9 mg/kg, p.o.) were given 1 h prior to dexfenfluramine (10 mg/kg, p.o.) using the same dosing regimen as described above. Sibutramine (9 mg/kg, p.o.; three times its ED
50 to inhibit food intake at 2 h) had no significant effect on the number or affinity of 5-HT re-uptake sites the brain regions studied. In contrast, dexfenfluramine at an equivalent dose (3 mg/kg, p.o.) significantly decreased the number of 5-HT re-uptake sites in frontal cortex (by 35%), hippocampus (by 47%) and hypothalamus (by 27%). This effect was dose-dependent with marked decreases (by 58–84%) in the number of sites following 10 mg/kg, p.o. These effects were not associated with changes in binding affinity. Fluoxetine (10 mg/kg, i.p.) completely blocked the effect of dexfenfluramine (10 mg/kg, p.o.) without having any significant effect alone. Sibutramine (9 mg/kg, p.o.) also blocked the effects of dexfenfluramine, although the reversal was only partial in frontal cortex, hippocampus and hypothalamus. Thus sibutramine, unlike dexfenfluramine, does not alter brain 5-HT re-uptake sites. Furthermore, sibutramine and fluoxetine protect against the deficits in 5-HT re-uptake sites produced by dexfenfluramine. These data provide further evidence that sibutramine is a 5-HT re-uptake inhibitor and it does not have neurotoxic potential.</description><subject>5-HT re-uptake sites</subject><subject>[ 3H]Paroxetine binding</subject><subject>Animals</subject><subject>Appetite Depressants - pharmacology</subject><subject>Biological and medical sciences</subject><subject>Brain - drug effects</subject><subject>Brain - metabolism</subject><subject>Cyclobutanes - pharmacology</subject><subject>Dexfenfluramine</subject><subject>Dexfenfluramine - antagonists & inhibitors</subject><subject>Dexfenfluramine - pharmacology</subject><subject>Fluoxetine</subject><subject>Fluoxetine - pharmacology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Neuropharmacology</subject><subject>Neurotransmitters. Neurotransmission. Receptors</subject><subject>Paroxetine - metabolism</subject><subject>Pharmacology. Drug treatments</subject><subject>Rat brain</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>selective serotonin reuptake inhibitors</subject><subject>Serotonin Receptor Agonists - pharmacology</subject><subject>Serotonin Uptake Inhibitors - pharmacology</subject><subject>Serotoninergic system</subject><subject>Sibutramine</subject><issn>0028-3908</issn><issn>1873-7064</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkcFu1TAQRS1ERV8LnwDyAiGQGhg7ieOsKlQVWqkSi5a15dhjMCTOw3ZQ-zH8a92XJ2DXla2ZMzNX9xLyksF7Bkx8uAbgsqp7kG8B3gFAzSt4QjZMdnXVgWieks1f5JAcpfSjQI1k8hk5ZNCLumvEhvy59sOSo558QGpnTDTMmVo0EXVCmr8jDcs0YKSzo211cUMjVss2659Ik8-F94FGnekQdfnpYE_o6EvTjct8i7msPaHbOGc0OVH9rUAp79ZadN74Uixduxi0dLgrxVuHocyuip6TA6fHhC_27zH5-un85uyiuvry-fLs41VlGs5yxbWDVkuO0A8csesQe216MFyaTou2H1opBAOOhjWix9bx1lgjrESwfND1MXmz7i1afi2Yspp8MjiOOuC8JMU6UXNZdwVsV9DEOaWITm2jn3S8UwzUQy5ql4t6MF0BqF0uCsrcq_2BZZjQ_je1BlGA13tAJ6NHF3UwPv3jGiGElAU7XTEsbvz2GFUyHkNxz8fisLKzf0TJPaO0rFY</recordid><startdate>20000101</startdate><enddate>20000101</enddate><creator>Cheetham, S.C</creator><creator>Viggers, J.A</creator><creator>Slater, N.A</creator><creator>Heal, D.J</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope></search><sort><creationdate>20000101</creationdate><title>Sibutramine does not decrease the number of 5-HT re-uptake sites in rat brain and, like fluoxetine, protects against the deficits produced by dexfenfluramine</title><author>Cheetham, S.C ; Viggers, J.A ; Slater, N.A ; Heal, D.J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c421t-2af05a82e09b2ee77ee9ac90c28c7a659b5866102ec1469e5f25cdc6d8e0d2ba3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>5-HT re-uptake sites</topic><topic>[ 3H]Paroxetine binding</topic><topic>Animals</topic><topic>Appetite Depressants - pharmacology</topic><topic>Biological and medical sciences</topic><topic>Brain - drug effects</topic><topic>Brain - metabolism</topic><topic>Cyclobutanes - pharmacology</topic><topic>Dexfenfluramine</topic><topic>Dexfenfluramine - antagonists & inhibitors</topic><topic>Dexfenfluramine - pharmacology</topic><topic>Fluoxetine</topic><topic>Fluoxetine - pharmacology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Neuropharmacology</topic><topic>Neurotransmitters. Neurotransmission. Receptors</topic><topic>Paroxetine - metabolism</topic><topic>Pharmacology. Drug treatments</topic><topic>Rat brain</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>selective serotonin reuptake inhibitors</topic><topic>Serotonin Receptor Agonists - pharmacology</topic><topic>Serotonin Uptake Inhibitors - pharmacology</topic><topic>Serotoninergic system</topic><topic>Sibutramine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cheetham, S.C</creatorcontrib><creatorcontrib>Viggers, J.A</creatorcontrib><creatorcontrib>Slater, N.A</creatorcontrib><creatorcontrib>Heal, D.J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><jtitle>Neuropharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cheetham, S.C</au><au>Viggers, J.A</au><au>Slater, N.A</au><au>Heal, D.J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sibutramine does not decrease the number of 5-HT re-uptake sites in rat brain and, like fluoxetine, protects against the deficits produced by dexfenfluramine</atitle><jtitle>Neuropharmacology</jtitle><addtitle>Neuropharmacology</addtitle><date>2000-01-01</date><risdate>2000</risdate><volume>39</volume><issue>11</issue><spage>2028</spage><epage>2035</epage><pages>2028-2035</pages><issn>0028-3908</issn><eissn>1873-7064</eissn><coden>NEPHBW</coden><abstract>The effect of sibutramine and dexfenfluramine on 5-HT re-uptake sites, labelled with [
3H]paroxetine, have been determined in various rat brain regions. In addition, the ability of fluoxetine and sibutramine to protect against the changes in [
3H]paroxetine binding produced by dexfenfluramine was examined. Sibutramine (9 mg/kg, p.o.) and dexfenfluramine (1, 3 and 10 mg/kg, p.o.) were administered twice daily (before 09.00 h and after 16.00 h) for four days, followed by a 14 day drug-free period. In the protection studies, fluoxetine (10 mg/kg, i.p.) and sibutramine (9 mg/kg, p.o.) were given 1 h prior to dexfenfluramine (10 mg/kg, p.o.) using the same dosing regimen as described above. Sibutramine (9 mg/kg, p.o.; three times its ED
50 to inhibit food intake at 2 h) had no significant effect on the number or affinity of 5-HT re-uptake sites the brain regions studied. In contrast, dexfenfluramine at an equivalent dose (3 mg/kg, p.o.) significantly decreased the number of 5-HT re-uptake sites in frontal cortex (by 35%), hippocampus (by 47%) and hypothalamus (by 27%). This effect was dose-dependent with marked decreases (by 58–84%) in the number of sites following 10 mg/kg, p.o. These effects were not associated with changes in binding affinity. Fluoxetine (10 mg/kg, i.p.) completely blocked the effect of dexfenfluramine (10 mg/kg, p.o.) without having any significant effect alone. Sibutramine (9 mg/kg, p.o.) also blocked the effects of dexfenfluramine, although the reversal was only partial in frontal cortex, hippocampus and hypothalamus. Thus sibutramine, unlike dexfenfluramine, does not alter brain 5-HT re-uptake sites. Furthermore, sibutramine and fluoxetine protect against the deficits in 5-HT re-uptake sites produced by dexfenfluramine. These data provide further evidence that sibutramine is a 5-HT re-uptake inhibitor and it does not have neurotoxic potential.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>10963746</pmid><doi>10.1016/S0028-3908(00)00032-0</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0028-3908 |
ispartof | Neuropharmacology, 2000-01, Vol.39 (11), p.2028-2035 |
issn | 0028-3908 1873-7064 |
language | eng |
recordid | cdi_proquest_miscellaneous_17632837 |
source | MEDLINE; Access via ScienceDirect (Elsevier) |
subjects | 5-HT re-uptake sites [ 3H]Paroxetine binding Animals Appetite Depressants - pharmacology Biological and medical sciences Brain - drug effects Brain - metabolism Cyclobutanes - pharmacology Dexfenfluramine Dexfenfluramine - antagonists & inhibitors Dexfenfluramine - pharmacology Fluoxetine Fluoxetine - pharmacology Male Medical sciences Neuropharmacology Neurotransmitters. Neurotransmission. Receptors Paroxetine - metabolism Pharmacology. Drug treatments Rat brain Rats Rats, Sprague-Dawley selective serotonin reuptake inhibitors Serotonin Receptor Agonists - pharmacology Serotonin Uptake Inhibitors - pharmacology Serotoninergic system Sibutramine |
title | Sibutramine does not decrease the number of 5-HT re-uptake sites in rat brain and, like fluoxetine, protects against the deficits produced by dexfenfluramine |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T05%3A12%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sibutramine%20does%20not%20decrease%20the%20number%20of%205-HT%20re-uptake%20sites%20in%20rat%20brain%20and,%20like%20fluoxetine,%20protects%20against%20the%20deficits%20produced%20by%20dexfenfluramine&rft.jtitle=Neuropharmacology&rft.au=Cheetham,%20S.C&rft.date=2000-01-01&rft.volume=39&rft.issue=11&rft.spage=2028&rft.epage=2035&rft.pages=2028-2035&rft.issn=0028-3908&rft.eissn=1873-7064&rft.coden=NEPHBW&rft_id=info:doi/10.1016/S0028-3908(00)00032-0&rft_dat=%3Cproquest_cross%3E17632837%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17632837&rft_id=info:pmid/10963746&rft_els_id=S0028390800000320&rfr_iscdi=true |